Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
IT0004147952
Tue, 03.01.2023
Newron Pharmaceuticals S.p.A.
Newron announces striking
six-month interim results from its exploratory clinical trial evaluating
evenamide as add-on therapy for patients with
treatment-resistant schizophrenia
Statistically significant, clinically meaningful improvements over baseline were seen
across efficacy endpoints after six months; continued improvement was seen when co [ … ]
Thu, 15.09.2022
Newron Pharmaceuticals S.p.A.
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended Jun [ … ]
Thu, 15.09.2022
Newron Pharmaceuticals S.p.A.
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended Jun [ … ]
Fri, 01.07.2022
Newron Pharmaceuticals S.p.A.
Newron extends Senior Management team and
strengthens commitment to ESG
Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is ex [ … ]
Fri, 01.07.2022
Newron Pharmaceuticals S.p.A.
Newron extends Senior Management team and
strengthens commitment to ESG
Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it is ex [ … ]
Tue, 07.06.2022
Newron Pharmaceuticals S.p.A.
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
Interim results show improved symptoms of psychosis in patients with chronic TRS
Study 014 represents first international trial of a New Chemical Entity (NCE) anti [ … ]
Tue, 05.04.2022
Newron Pharmaceuticals S.p.A.
Newron announces AGM 2022 results
Milan, Italy - April 5, 2022 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that its shareholders approved all motions on the agenda of t [ … ]
Tue, 15.03.2022
Newron Pharmaceuticals S.p.A.
Newron announces 2021 financial results and provides outlook for 2022
Milan, Italy, March 15, 2022, 7 am CET - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina [ … ]
Wed, 01.12.2021
Newron Pharmaceuticals S.p.A.
Change in Newron Board of Directors
Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Dir [ … ]
Mon, 18.10.2021
Newron Pharmaceuticals S.p.A.
Newron Receives Fifth Tranche from Financing Agreement with
European Investment Bank (EIB)
Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous syste [ … ]